Industry Newsai drug discoverypharma biotechinsilico medicinecornerstone investors
InSilico Medicine Launches Hong Kong IPO With Major Cornerstones
7.0
InSilico Medicine launched an IPO in Hong Kong, filing to list on the HKEX Main Board under code 3696 with a planned December 30 listing. The global offering of about 94.69 million shares at HK$24.05 seeks up to HK$2.3 billion (~US$295 million) and secured US$115 million from 15 cornerstone investors including Eli Lilly and Tencent. The AI drug-discovery firm runs the Pharma.AI platform and reported 2024 revenue of US$85.83 million.
Key Points
- 1Lists about 94.69 million shares at HK$24.05, aiming to raise up to HK$2.3 billion.
- 2Attracts US$115 million from 15 cornerstone investors including Eli Lilly, Tencent, Temasek.
- 3Operates Pharma.AI with 30+ programs; Rentosertib granted Breakthrough Therapy designation in China.
Scoring Rationale
High industry relevance and strong cornerstone backing; score limited by being a financing event rather than a technological breakthrough.
Sources
Public references used for this report.
Practice with real FinTech & Trading data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
Active Verified Users by Income TierEasyTechnology Stocks with High BetaMediumPortfolio Performance ScorecardHard
250 free problems · No credit card
See all FinTech & Trading problems
